Letaplimab represents a novel medical method for treating complement-mediated conditions. This antibody targets complement component C1q, a essential component of the complement pathway, aiming to disrupt its early https://deannahkeg874871.mpeblog.com/73614969/letaplimab-a-groundbreaking-therapeutic-strategy